Project Grant R01HL182805
Award Date 8/24/26
Completion Date 5/31/31
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded The Regents Of The University Of Colorado, doing business as University Of Colorado-Denver, $786,950 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct Project Grant R01HL184900, investigating mitochondrial uncoupling protein-2 (UCP2) as a metabolic regulator of fibroblast activation in idiopathic pulmonary fibrosis (IPF). The research defines UCP2's transport function and its role in sustaining...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $676,602 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of LYVE1-expressing interstitial macrophage-driven vascular remodeling in pulmonary hypertension. The research examines the role of LYVE1+ interstitial macrophages (IMs) in pulmonary hypertension, a deadly, incurable disease of the pulmonary...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $134,439 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support mentoring in translational interstitial lung disease research. The award funds development of protein-based biomarkers for patients with fibrotic interstitial lung disease (ILD) through two primary objectives: deriving and validating a proteomic biomarker to predict ILD in patients presenting with...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $212,782 on September 9, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate developmental dysanapsis in lung development throughout the lifespan in experimental bronchopulmonary dysplasia. The research examines whether intra-amniotic endotoxin causes persistent dysanaptic growth of airways, distal parenchyma, and...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $746,392 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to delineate ventilator-induced lung injury arising from specific types of ventilator dyssynchrony—double-triggered, flow-limited, and ineffective-triggered breaths. The research addresses the gap in understanding dose-response relationships between...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $189,000 Project Grant to the University of Colorado-Denver for a two-year research initiative (August 1, 2025 – July 31, 2027) under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports research investigating the role of aldehyde dehydrogenase 2 (ALDH2) in the pathogenesis and resolution of fibroproliferative acute respiratory distress syndrome (FP-ARDS). The research builds on...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....